- Open Access
Cancer patients' attitudes towards Chinese medicine: a Hong Kong survey
Chinese Medicinevolume 4, Article number: 25 (2009)
This article reports a survey conducted in Hong Kong on the cancer patients' attitudes towards Chinese medicine treatment.
Cancer patients from three Chinese medicine clinics and one oncology clinic were interviewed with a structured questionnaire.
Of a total of 786 participants included in the study, 42.9% used Western medicine only; 57.1% used at least one form of Chinese medicine; 5 participants used Chinese medicine only; and 56.5% used Chinese medicine before/during/after Western medicine treatment. Commonly used Western medicine and Chinese medicine treatments included chemotherapy (63.7%), radiotherapy (62.0%), surgery (57.6%), Chinese herbal medicine (53.9%) and Chinese dietary therapy (9.5%). Participants receiving chemotherapy used Chinese medicine (63.3%) more than those receiving any other Western medicine treatments. Spearman correlation coefficients showed that the selection of Chinese medicine was associated with the cancer type (rs = -1.36; P < 0.001), stage (rs = 0.178; P < 0.001), duration (rs = -0.074; P = 0.037), whether receiving chemotherapy (rs = 0.165; P < 0.001) and palliative therapy (rs = 0.087; P = 0.015). Nearly two-thirds of the participants (N = 274) did not tell their physicians about using Chinese medicine. Over two-thirds of all participants (68.2%) believed that integrated Chinese and Western medicine was effective.
Chinese medicine is commonly used among Hong Kong cancer patients. The interviewed cancer patients in Hong Kong considered integrative Chinese and Western medicine is an effective cancer treatment.
Cancer is a major disease in Hong Kong with great social and economic burden. According to the Hong Kong Cancer Registry, 23,750 new cancer cases and 12,093 cancer deaths were recorded in 2006. New cancer cases in Hong Kong has been rising at a annual rate of 2% . While surgery, radiotherapy and chemotherapy remained to be conventional cancer treatments, 80% of the cancer patients around the world consult complementary and alternative medicine (CAM) for more treatment options [2–5]. Chinese medicine, one of the most popular CAMs, is an available option in many cancer centres in Asia [6–8], North America [9, 10], and Europe .
Chinese medicine and Western medicine differ fundamentally in their etiological concepts and therapeutic approaches. In Western medicine, cancer is perceived as uncontrolled growth of malignant cells which may be treated by surgery, chemotherapy, and radiotherapy . According to Chinese medicine theory, cancer is the manifestation of a qi disturbance which may be treated by mobilizing qi. Study results support the use of Chinese medicine to treat liver cancer and leukaemia [12, 13], and recent meta-analyses demonstrated that Chinese medicine improved tumor response to chemotherapy as well as patient's survival rates [14, 15]. Five common Chinese medicine modalities, namely Chinese herbal medicine, acupuncture and moxibustion, therapeutic massage, qigong and Chinese dietary therapy have been used to treat cancer . Moreover, acupuncture relieves pain and acute vomiting during conventional cancer treatment [15, 17]
While some researchers suggest that Chinese medicine should be integrated into a comprehensive cancer treatment scheme , cancer patients' attitude towards Chinese medicine is largely unknown. The present study aimed to reveal the prevalence and pattern of the use of Chinese medicine among cancer patients in Hong Kong and to assess their attitudes and intentions about such use.
This study was approved by the Committee on the Use of Human and Animal Subjects in Teaching and Research of the Hong Kong Baptist University (HKBU) and the Research Ethics Committee of the Hospital Authority (HA) Hong Kong. Between April 2008 and August 2008, all cancer patients attending any of the three HKBU Chinese medicine clinics and the outpatient clinics of the Department of Clinical Oncology in Queen Elizabeth Hospital (QEH) were invited to participate in this cross-sectional survey.
Oral informed consent was obtained from cancer patients before participation. Each participant completed a questionnaire, which was then checked by one of the authors (YCL). Completed and checked questionnaires were coded to mask patients' identities. Another author (CWC) double-checked the collected questionnaire to ensure good quality.
In this paper, Chinese medicine user is defined as the person who receives treatments of Chinese herbal medicine, acupuncture and moxibustion, therapeutic massage, qigong, Chinese dietary therapy and/or other therapies that are based on the theory of Chinese medicine.
The development of the questionnaire (in Chinese language) included four stages as follows (1) a draft questionnaire was prepared; (2) the questionnaire was reviewed by Chinese medicine experts (N = 6) and Western medicine practitioners (N = 2) were collected; (3) the draft questionnaire was revised by the authors and tested on a small group (N = 10) of cancer patients;.(4) the questionnaire was finalized. The final questionnaire consisted of three parts. The first part was about background information of the participants (e.g. age, gender, marital status, educational level), type of cancer, date of diagnosis, use of Western medicine cancer treatment and/or Chinese medicine treatment. The second part focused on participants' perception of Western medicine treatment and/or Chinese medicine treatment, such as times to initiate Chinese medicine treatment, motivations for using Chinese medicine, whether or not their physicians were told about the use of Chinese medicine and why, responses from physicians, reasons for choosing Western medicine treatment and/or Chinese medicine treatment, satisfaction with the treatment. Finally, participants were asked whether they intended to continue or stop their use of Western medicine treatment and/or Chinese medicine treatment, or other CAM therapies in the future, and their opinion on the effectiveness of the integration of Chinese and Western medicine in their cancer treatment. In the third part, participants were asked to express their views on the integration of Chinese medicine and Western medicine in cancer treatment.
Data management and statistical analyses
YCL, one of the authors, entered the data into an Access (Microsoft, USA) database, and CWC, another author, checked the data independently. All data disagreements were resolved through further checks against raw data. Data were analyzed with the Statistical Package for Social Sciences program (SPSS 13.0, SPSS, USA). Demographic and clinical characteristic differences between Western medicine and Chinese medicine users were assessed with chi-square test. Spearman correlation between the use of Chinese medicine and other variables of interest was determined. All statistical tests were two-tailed with a confidence level of alpha of 0.05.
Demographic and clinical characteristics of study participants
Seven hundred and ninety-one (791) questionnaires were distributed, of which 786 (99.4%) received responses. Common cancers among the participants were lung cancer, breast cancer, colorectal cancer and nasopharyngeal cancer (Table 1).
Compared with Western medicine users, Chinese medicine users were better educated among whom Stage III or IV lung cancer, breast cancer and nasopharyngeal cancer and cancers which had been diagnosed within the last 36 months (P < 0.05).
Prevalence and pattern of treatment
Nearly all participants (99.4%) used western medicine; 56.5% (N = 444) combined Western medicine with Chinese medicine, while 42.9% (N = 337) used Western medicine alone. Only 0.6% (N = 5) of the participants used Chinese medicine alone. This pattern was probably skewed towards Western medicine users because 85.1% (N = 669) participants were recruited from Western medicine clinics. Nevertheless, almost half of those patients received Chinese medicine treatment. Furthermore, the Spearman correlation coefficient study showed type of cancer (rs = -1.36; P < 0.001), stage of cancer (rs = 0.178; P < 0.001), time since diagnosis (rs = -0.074; P = 0.037) were correlated with the use of Chinese medicine (Tables 1, 2, 3).
The use profile of Western medicine treatment among the participants was as follows: chemotherapy (63.7%), radiotherapy (62.0%), surgery (57.6%), endocrine therapy (10.7%), and palliative therapy (1.5%) (Table 4). Chinese herbal medicine (94.4%) was the most used Chinese medicine modality, followed by Chinese dietary therapy (16.7%) qigong (8.9%), acupuncture and moxibustion (4.7%) and therapeutic massage (2.4%) (Table 3). Results showed that 62.6% of the participants received only Western medicine and 54.3% of the participants (N = 244) received both Western medicine and Chinese medicine were satisfied with their treatments (Figure 1).
Among the participants who used Chinese medicine (N = 449), 67.9% (N = 305) as recommended by relatives, ward-mates or others, while 52.1% (N = 234) made their own choice. Only 3.8% (N = 17) of the participants were recommended to use Chinese medicine by their physicians. Nearly two-thirds of the participants (N = 274) did not tell their physicians about using Chinese medicine. Of 175 participants who consulted their physicians about their use of Chinese medicine, 49.7% (N = 87) physicians were neutral, 29.1% (N = 51) were for, whereas 20.0% (N = 35) against their use of Chinese medicine (Table 5).
Factors contributing to treatment modality preference
With the hopes to reduce side-effects from Western medicine (65.5%), suppress tumor progression (60.8%), relieve symptoms (57.5%) and improve quality of life (48.4%), 54.2% of the participants (N = 426) preferred combined Chinese medicine and Western medicine treatments. Out of 347 (44.1%) participants who used Western medicine only, 67.7% did so because they believed that Western medicine alone could suppress tumor progression (Table 6).
Over two-thirds of all participants (68.2%) believed that integrated Chinese and Western medicine was effective. Participants who were ambivalent about integrated Chinese and Western medicine effectiveness accounted for 31.4% (N = 245), while only 0.4% (N = 3) thought integrated medicine would not be effective (Figure 2).
A total of 469 participants (59.7%) claimed that they would continue or try Chinese medicine as an alternative therapy in the future, while 63 participants (8.0%) would not consider using Chinese medicine only (Figure 3).
Demand for integrative Chinese-Western medicine treatment
Regarding whether or not the Hong-Kong government should further promote the integration of Chinese medicine and Western medicine in cancer treatment, 690 participants (87.8%) agreed, 92 (11.7%) had no opinion, while only 4 (0.5%) thought it was unnecessary.
Among many studies reporting the use of CAM to treat cancer patients [2–7, 9, 19–21], few reports were based on large-scale survey. This survey interviewed a large number of patients (N = 786) with various types of cancers to evaluate the characteristics of their treatment as well as their attitudes towards Chinese medicine treatment. The present study indicates that the use of Chinese medicine in cancer treatment in Hong Kong (57.1%) is much more than that in Japan (7.1%) , but lower than that in the mainland China (100%) . As overseas Chinese often think of Chinese medicine as their first choice of CAM [22, 23], this difference in the use of Chinese medicine may be due to socio-cultural difference among ethnics groups  rather than regional differences in medical systems.
Findings that cancer patients in Hong Kong favored Chinese herbal medication are consistent with previous studies [9, 22]. The present study discovered that nearly half (49.93%) of the participants recruited from Western medicine clinics used Chinese medicine. Several factors were found to encourage the use of Chinese medicine among cancer patients [7, 20, 24, 25], such as recommendations from the relatives and ward-mates, patients' own willingness, and advice from physicians.
Sixty-one per cent (61.0%) of the participants never talked to their physicians about their use of Chinese medicine. Half of the physicians (49.7%) held neutral opinions towards Chinese medicine use; one-third (29.1%) accepted Chinese medicine use and 20% rejected it. Seventy percent (70%) of the participants believed that integration of Chinese medicine and Western medicine would have positive effects in cancer treatment. Approximately 90% of all participants thought that the Hong Kong government should develop integrative Chinese and Western medicine in cancer treatment. As such, we propose that communication among patients, physicians and Chinese medicine practitioners should be encouraged.
Biases may exist in this study as a result of the non-randomized recruitment method. A total of 117 (14.9%) participants were recruited from three HKBU Chinese medicine clinics. The use of Chinese medicine among these participants may be higher than the participants from ordinary clinics. The recruitment from the Oncology Outpatient Department excluded those patients from the palliative day-care clinics. Nevertheless, among the participants (N = 669) recruited from Western medicine clinics, nearly half (49.93%) did use Chinese medicine. Even though the sample may not be representative of all cancer patients in Hong Kong, the large scale and interesting findings of this study does warrant a more structured and population-based sample in the future.
Our findings indicate that most cancer patients in Hong Kong considered integrative Chinese and Western medicine as an effective cancer treatment. Randomized controlled trials to evaluate Chinese medicine treatments, establishment of integrative Chinese and Western medical facilities, and public education about Chinese medicine are greatly demanded.
Hong Kong Cancer Registry. (Assessed on 27 Jan 2009), [http://www3.ha.org.hk/cancereg]
Boon H, Brown JB, Gavin A, Kennard MA, Stewart M: Breast cancer survivors' perceptions of complementary/alternative medicine (CAM): making the decision to use or not to use. Qual Health Res. 1999, 9 (5): 639-653. 10.1177/104973299129122135.
Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998, 83 (4): 777-782. 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O.
Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implication for oncology. J Clin Oncol. 2000, 18 (13): 2505-2514.
Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E: Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005, 16 (4): 655-663. 10.1093/annonc/mdi110.
Xu W, Towers AD, Li P, Collet JP: Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China. Eur J Cancer Care. 2006, 15: 397-403. 10.1111/j.1365-2354.2006.00685.x.
Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S: Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005, 23 (12): 2645-2654. 10.1200/JCO.2005.04.126.
Tan KY, Liu CB, Chen AH, Ding YJ, Jin HY, Seow-Choen F: The role of traditional Chinese medicine in colorectal cancer treatment. Tech Coloproctol. 2008, 12 (1): 1-6. 10.1007/s10151-008-0392-z.
Cui Y, Shu XO, Gao Y, Wen W, Ruan ZX, Jin F, Zheng W: Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat. 2004, 85: 263-270. 10.1023/B:BREA.0000025422.26148.8d.
Swarup AB, Barrett W, Jazieh AR: The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol. 2006, 29 (5): 468-473. 10.1097/01.coc.0000221326.64636.b2.
Luk JM, Wang XL, Liu P, Wong KF, Chan KL, Tong Y, Hui CK, Lau GK, Fan ST: Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int. 2007, 27 (7): 879-890. 10.1111/j.1478-3231.2007.01527.x.
Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z: Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. PNAS. 2008, 105 (12): 4826-4831. 10.1073/pnas.0712365105.
Shu X, McCulloch M, Xiao H, Broffman M, Gao J: Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther. 2005, 4: 219-229. 10.1177/1534735405279927.
McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM: Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006, 24 (3): 419-430. 10.1200/JCO.2005.03.6392.
Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM: Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life - a systematic review. J Pain Symptom Manage. 2000, 20 (5): 374-387. 10.1016/S0885-3924(00)00190-1.
Sagar SM, Wong R: Chinese medicine and supportive cancer care:a model for an evidence-based, integrative approach. Evidence-Based Integ Med. 2003, 1 (1): 11-25. 10.2165/01197065-200301010-00005.
Macek C: East meets west to balance immunologic yin and yang. JAMA. 1984, 251 (4): 433-435. 10.1001/jama.251.4.433.
Wong R, Sagar CM, Sagar SM: Integration of Chinese medicine into supportive cacer care: a modern role for an ancient tradition. Cancer Treat Rev. 2001, 27 (4): 235-246. 10.1053/ctrv.2001.0227.
Maciocia G: The Foundations of Chinese medicine: A Comprehensive Text for Acupuncturists and Herbalists. 1989, New York: Churchill Livingstone
Humpel N, Jones SC: Gaining insight into the what, why and where of complementary and alternative medicine use by cancer patients and survivors. Eur J Cancer Care. 2006, 15 (4): 362-268. 10.1111/j.1365-2354.2006.00667.x.
Gözüm S, Arikan D, Büyükavci M: Complementary and alternative medicine use in pediatric oncology patients in Eastern Turkey. Cancer Nurs. 2007, 30 (1): 38-44. 10.1097/00002820-200701000-00007.
Simpson PB: Family beliefs about diet and traditional Chinese medicine for Hong Kong women with breast cancer. Oncol Nurs Forum. 2003, 30 (5): 834-840. 10.1188/03.ONF.834-840.
Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D: Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst. 2000, 92 (1): 42-47. 10.1093/jnci/92.1.42.
Ma GX: Between two worlds: the use of traditional and western health services by Chinese immigrants. J Community Health. 1999, 24 (6): 421-437. 10.1023/A:1018742505785.
Engdal S, Steinsbekk A, Klepp O, Nilsen OG: Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer. 2008, 16 (7): 763-769. 10.1007/s00520-007-0371-3.
This research was financially supported by the Qin Xiao-ling Medical Research Foundation.
The authors declare that they have no competing interests.
Bian ZX and Law CK conceived the study design, trained the research assistants, developed the study protocol and finalized the manuscript. Lam YC carried out the survey, performed data management and drafted the manuscript. Cheng CW checked the raw data and performed statistical analysis with assistance of Peng H. Huang XZ helped with participant recruitment. All authors read and approved the final version of the manuscript.